Supports early stage clinical trials of pharmacologic or neuromodulatory device-based interventions for mental disorders. Requires an experimental therapeutics approach evaluating both clinical effects and mechanisms of action, emphasizing dose-dependent neurophysiological, clinical, or behavioral outcomes. Clinical trial conduct is mandatory under this funding opportunity.
Eligible applicants include a wide range of organizations such as for-profit entities, small businesses, nonprofits, tribal governments, educational institutions, state and local governments, and certain federal agencies. Non-U.S. entities and regional organizations are also eligible.
